In this video Cogstate CSO, Prof Paul Maruff, discusses the recent Clinical Trials in Alzheimer’s Disease (CTAD) conference and the exciting scientific contributions from Cogstate, as featured in the following presentations:
- Use of the International Shopping List Test as the objective assessment of cognitive impairment to identify subjects with early Alzheimer’s disease in the Eisai elenbecestat MissionAD phase 3 clinical trials
- Utility of the International Shopping List Test for detection of memory impairment associated with prodromal and early Alzheimer’s disease in clinical trials
- Phase IIa study results with the glutaminylcyclase inhibitor PQ912 in early Alzheimer’s Disease
- Online study partner-reported subjective cognitive decline can help identify potential Alzheimer’s clinical trial participants
- UB-311 active vaccine generates titers specific for Aβ oligomers and fibrils without evidence of ARIA-E or encephalopathy in a completed Phase 1 and an ongoing Phase 2a study in Alzheimer’s disease
- Rapid, Remote, and Repeatable: Smartphone-Based “Burst” Cognitive Assessments for Global AD Prevention Trials
